FPI-2265 not checked

Fusion Pharmaceuticals Inc. · Ac225-PSMA I&T

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225”In the company’s words, NCT05219500 on ClinicalTrials.gov
Tested for
Metastatic Castration-resistant Prostate Cancer (2 trials), Metastatic Castration Resistant Prostate Cancer
Main trialPhase 2
“The treatment regimen will consist of 4 doses of FPI-2265”In the company’s words, NCT05219500 on ClinicalTrials.gov
Other names
Ac225-PSMA I&T

Other drugs for Metastatic Castration-resistant Prostate Cancer

All 194 drugs for Metastatic Castration-resistant Prostate Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 30 May 2025 Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Phase 2Active, not recruiting 23 Dec 2026 FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 2Active, not recruiting May 2027 FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow FPI-2265

Following is part of Solo: you see every change to FPI-2265 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in